Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

September 02, 2015 11:27 PM ET


Company Overview of CytomX Therapeutics, Inc.

Company Overview

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops novel class of antibody therapeutics based on its Probody technology platform that address clinically-validated cancer targets in immuno-oncology, such as PD-L1, as well as novel targets, comprising CD-166. In addition it has strategic collaborations with Bristol-Myers Squibb Company, Pfizer Inc., and ImmunoGen, Inc. to develop selected Probody therapeutics. The company was founded in 2008 and is headquartered in South San Francisco, California.

343 Oyster Point Boulevard

Suite 100

South San Francisco, CA 94080-1913

United States

Founded in 2008





Key Executives for CytomX Therapeutics, Inc.

Chief Executive Officer, President and Director
Age: 48
Co-Founder and Director
Age: 79
Founder and Member of Scientific Advisory Board
Chief Financial Officer
Age: 42
Chief Scientific Officer and Head of Research & Early Development
Age: 59
Compensation as of Fiscal Year 2015.

CytomX Therapeutics, Inc. Key Developments

CytomX Therapeutics, Inc. Appoints Rachel Humphrey as Chief Medical Officer

CytomX Therapeutics, Inc. announced that Rachel Humphrey, M.D., previously a member of the company's Board of Directors, has been appointed chief medical officer. Dr. Humphrey formerly led immuno-oncology at Eli Lilly and AstraZeneca, and also oversaw clinical development of Yervoy (ipilmumab), the first FDA approved checkpoint inhibitor, at Bristol-Myers Squibb and the development of Nexavar (sorafenib) at Bayer. Dr. Humphrey recently held positions as vice president and head of immuno-oncology at Eli Lilly and at AstraZeneca, where she was responsible for building the immuno-oncology departments and supervising the strategies and designs for all the immuno-oncology agents in development. She previously served as vice president of product development at Bristol-Myers Squibb, where she led all aspects of the clinical development of Yervoy through the submission of global biologics license applications and global launch. At Bayer, Dr. Humphrey supervised the early and late stage clinical development of Nexavar for treatment of renal cell carcinoma. She began her career as an oncology fellow and staff physician at the National Cancer Institute.

CytomX Announces Management Team Promotions

CytomX Therapeutics, Inc. announced the promotion of several members of its leadership team. Debanjan Ray, who previously served as vice president of business development and alliance management, has been promoted to senior vice president of corporate development and strategy. Prior to joining CytomX, Mr. Ray held positions as the vice president of business development at Itero Biopharmaceuticals and as associate director of business development at Portola Pharmaceuticals. Bryan Irving, Ph.D., who previously served as senior director of cancer immunology, has been promoted to vice president of cancer immunology. Prior to joining CytomX, Dr. Irving conducted research at Genentech that resulted in the anti-PD-L1 antibody, atezolizumab, currently in clinical development, and held positions in academia where he conducted influential research into the single-chain chimeric antigen receptor (CAR) technology now being used in patients' T cells to treat hematologic malignancies. Jon Terrett, Ph.D., who previously served as senior director of oncology, has been promoted to vice president of oncology discovery. Prior to joining CytomX, Dr. Terrett was chief scientific officer of Oxford BioTherapeutics and served as a director for each of Medarex, CellTech and Oxford GlycoSciences. Carol Talkington Verser, Ph.D., who previously served as senior director of intellectual property, has been promoted to vice president of intellectual property. Prior to joining CytomX, Dr. Verser held positions as executive vice president, intellectual property and business development, at Heska Corporation and as patent agent and technical specialist at Sheridan Ross.

CytomX Therapeutics, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-02-2015 02:30 PM

CytomX Therapeutics, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-02-2015 02:30 PM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Sean A. McCarthy, Chief Executive Officer and Director.

Similar Private Companies By Industry

Company Name Region
UTC Laboratories LLC United States
Jantibody Therapeutics LLC United States
Boston BioCom LLC United States
PathoGn, Inc. United States
Antria, Inc. United States

Recent Private Companies Transactions

Private Placement
June 12, 2015
Private Placement
February 11, 2015
Private Placement
December 22, 2014

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CytomX Therapeutics, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at